Status:
COMPLETED
Candesartan Effect in Second Stage Arterial Hypertension
Lead Sponsor:
AstraZeneca
Conditions:
Stage II Hypertension
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
Eligibility Criteria
Inclusion
- Stage II essential hypertension (SBP≥ 160 or DBP≥100 mmHg), untreated, or treated with a maximum of 2 class of antihypertensive drugs
Exclusion
- Current serum-creatinine \>3 mg/dL, Current serum-potassium \>5.5 mmol/L, 16.
- Pregnant or lactating women or women of childbearing potential who were not protected from pregnancy
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT00621153
Start Date
February 1 2008
End Date
March 1 2009
Last Update
March 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Seoul, South Korea